A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2004
12/29/2004	EP1490111A2 Edg-receptor agonists for the treatment of hypertension
12/29/2004	EP1490101A1 Methods of enhancing immune induction involving mda-7
12/29/2004	EP1490095A1 Stable pharmaceutical composition containing factor viii
12/29/2004	EP1490093A1 Methods and compositions for the treatment of ischemia
12/29/2004	EP1490090A2 Active agent delivery systems and methods for protecting and administering active agents
12/29/2004	EP1490085A2 Fc receptor homolog, reagents, and uses thereof
12/29/2004	EP1490084A2 Compositions and methods for regulating thyroid hormone metabolism and cholesterol and lipid metabolism via the nuclear receptor car
12/29/2004	EP1490083A1 Microgel particles for the delivery of bioactive materials
12/29/2004	EP1490081A1 Isolation of a dual cox-2 and 5-lipoxygenase inhibitor from acacia
12/29/2004	EP1490080A1 A process for the extraction of anthocyanins from black rice and composition thereof
12/29/2004	EP1490076A2 Novel metabolic targets and markers
12/29/2004	EP1490075A2 Bioadhesive directed somatic cell therapy
12/29/2004	EP1490073A2 Serotonin and catecholamine system segment optimization techonology
12/29/2004	EP1490072A1 Novel therapeutical use of agonist ligands specific to g2a receptor
12/29/2004	EP1490071A2 Theraputic methods and uses of sapogenins and their derivatives
12/29/2004	EP1490070A2 Use of conjugated estrogens in combination with trimegestone in hormone replacement therapy
12/29/2004	EP1490069A2 Alpha aed and beta aed regulation of nuclear transcription, gene regulation, and/or gene expression
12/29/2004	EP1490068A1 Powder composition comprising zaleplon of defined particle size distribution and pharmaceutical products made therefrom
12/29/2004	EP1490067A2 Use of tyrosine kinase inhibitors for treating substance use disorders
12/29/2004	EP1490066A1 Use of ranolazine for the preparation of a medicament for the treatment of arrhythmias
12/29/2004	EP1490065A1 Benzylimidazolyl substituted 2-quinolinone and quinazolinone derivatives for use as farnesyl transferase inhibitors
12/29/2004	EP1490064A1 Substituted pyridinones as modulators of p38 map kinase
12/29/2004	EP1490063A1 Use of proton pump inhibitors for the treatment of noncardiac chest pain
12/29/2004	EP1490062A1 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
12/29/2004	EP1490061A1 Pharmaceutical compositions comprising a benzofuran derivative and their use for the treatment of attention deficit/hyperactivity disorder
12/29/2004	EP1490060A1 Antidiabetic agents
12/29/2004	EP1490059A1 Parenteral, intravenous, and oral administration of oxazolidinones for treating diabetic foot infections
12/29/2004	EP1490058A1 Peroxisome proliferator activated receptor modulators
12/29/2004	EP1490057A1 Method for treating cognitive disorders
12/29/2004	EP1490056A1 N-'4-(2-imino-pyrrolidin-1-yl)phenyl)-acetamide and corresponding piperidine derivatives as factor xa inhibitors for the treatment of thrombo-embolic diseases
12/29/2004	EP1490055A1 Use of selective ep4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension
12/29/2004	EP1490054A2 Hemiasterlin derivatives and uses thereof in the treatment of cancer
12/29/2004	EP1490053A1 Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and radiotherapy
12/29/2004	EP1490052A1 Device for the transdermal administration of a rotigotine base
12/29/2004	EP1490051A1 Use of topoisomerase inhibitors and heat shock protein 90 inhibitors for use in chemotherapy
12/29/2004	EP1490050A2 Methods for alzheimer's disease treatment and cognitive enhancement
12/29/2004	EP1490049A1 Citalopram for the treatment of elevated blood pressure
12/29/2004	EP1490048A1 Pharmaceutical composition for preventing or treating respiratory disease
12/29/2004	EP1490047A2 Certain pharmaceutically useful substituted aminoalkyl heterocycles
12/29/2004	EP1490046A1 Medicine based on diethylaminoethanol derivatives and its use for the prevention and treatment of inflammatory and degenerative diseases
12/29/2004	EP1490045A1 In vivo use of glutathionone s-transferase activated nitric oxide donors
12/29/2004	EP1490044A1 Combination therapy for the treatment of conditions with pathogenic inflammatory components
12/29/2004	EP1490043A2 Spirocyclic amides as cannabinoid receptor modulators
12/29/2004	EP1490042A2 Use of ltb4 antagonists in veterinary medicine
12/29/2004	EP1490041A1 Treatment of female sexual dysfunction
12/29/2004	EP1490040A2 Anti-inflammatory formulations
12/29/2004	EP1490037A1 Taste masked veterinary solid compositions
12/29/2004	EP1490036A1 Sustained release formulation of tramadol
12/29/2004	EP1490035A1 Intraorally disintegrating valdecoxib compositions
12/29/2004	EP1490034A1 Novel pharmaceutical compositions for antihistaminic-decongestant combination and method of making such compositions
12/29/2004	EP1490033A1 No-donating nsaids adsorbed into carrier particles
12/29/2004	EP1490031A1 Fast melt multiparticulate formulations for oral delivery
12/29/2004	EP1490030A1 Nanoparticulate compositions of angiogenesis inhibitors
12/29/2004	EP1490029A1 Controlled release drug delivery system of pravastatin
12/29/2004	EP1490027A1 Methods for entrapment of bioactive agent in a liposome or lipid complex
12/29/2004	EP1490025A2 Nanoparticulate compositions of map kinase inhibitors
12/29/2004	EP1490024A1 Effervescent compositions comprising bisphosphonates and methods related thereto
12/29/2004	EP1490015A2 Novel 2-amino-9-((2-hydroxymethyl) cyclopropylidenemethyl) purines as antiviral agents
12/29/2004	EP1490013A2 Methods, compositions, and kits for enhancing oligonucleotide-mediated nucleic acid sequence alteration using compositions comprising a histone deacetylase inhibitor, lambda phage beta protein, or hydroxyurea
12/29/2004	EP1489988A1 Dispensing apparatus and cartridge
12/29/2004	EP1489924A2 Bioavailability/bioefficacy enhancing activity of cuminum cyminum and extracts and fractions thereof
12/29/2004	EP1489915A1 Treatment and prevention of inflammatory disorders
12/29/2004	EP1439818B1 Chewable tablet containing lysine
12/29/2004	EP1414836B1 Process for the preparation of l-ribavirin
12/29/2004	EP1379220B1 Inhalation capsules
12/29/2004	EP1373259B1 Pyridazinone aldose reductase inhibitors
12/29/2004	EP1368046B1 Pharmaceutical formulation and the use thereof for preparing a medicament for the treatment of cardiovascular diseases
12/29/2004	EP1343516A4 Analogues of thiocoraline and be-22179
12/29/2004	EP1334094B1 Cholesterol lowering benzo[b]thiophenes and benzo[d]isothiazoles
12/29/2004	EP1328528B1 Pharmaceutical compositions comprising clavulanic acid
12/29/2004	EP1328506B1 Intermediates for use in retinoid synthesis
12/29/2004	EP1311265B1 Pharmaceutical compositions for treating neurological disorders
12/29/2004	EP1289931B1 Double salts of fumaric acid with a carnitine and an amino acid and food supplements, dietary supplements and drugs containing same
12/29/2004	EP1287827B1 Immunopotentiator
12/29/2004	EP1285917B1 Process for producing carbostyril derivative
12/29/2004	EP1282612B1 Alkynyl phenyl heteroaromatic glucokinase activators
12/29/2004	EP1274456B1 Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies
12/29/2004	EP1267931B1 Rhodamine derivatives for photodynamic diagnosis and treatment
12/29/2004	EP1265891B1 Novel lipoic acid heterocyclic or benzene derivatives, preparation and use thereof as medicines
12/29/2004	EP1263723A4 Ningalin b analogs employable for reversing multidrug resistance
12/29/2004	EP1257539B1 Amino pyrazole derivatives useful for the treatment of obesity and other disorders
12/29/2004	EP1248623B1 Treatment of diabetic ulcers
12/29/2004	EP1244657B1 Sulfonamides and derivatives thereof that modulate the activity of endothelin
12/29/2004	EP1244444B1 Process for formulation of carbapenem antibiotic compositions
12/29/2004	EP1233769A4 Novel compounds
12/29/2004	EP1230224B1 Substituted 5-benzyl-2,4-diaminopyrimidines
12/29/2004	EP1226138B1 Fab i inhibitors
12/29/2004	EP1226136B1 Tyrosine kinase inhibitors
12/29/2004	EP1225902B1 Ciclesonide contained pharmaceutical composition for application to mucosa
12/29/2004	EP1225890B1 Rivastigmine for the treatment of ocular disorders
12/29/2004	EP1225882A4 Selective cox-2 inhibitory novel esters from indolealkanols and novel amides from indolealkylamines
12/29/2004	EP1216234B1 Mediators of hedgehog signaling pathways, compositions and uses related thereto
12/29/2004	EP1216048B1 Solid lipid formulations comprising an inhibitor of lipases and a fatty acid ester of polyols
12/29/2004	EP1214345B1 Agents for treating human diseases, especially for treating tumors such as colonic cancers and melanomas or for regenerating tissue and promoting hair growth
12/29/2004	EP1210069B1 Large porous particles obtainable by spray-drying and suitable for pulmonary administration
12/29/2004	EP1206442A4 Substituted chiral allosteric hemoglobin modifiers
12/29/2004	EP1204646B1 1,4,5,6 -tetrahydropyrimidine derivative as a vitronectin inhibitor
12/29/2004	EP1202727B1 Use of agonists of gabab receptors and pharmaceutically acceptable derivatives thereof, in the therapy of maintaining nicotine abstinence in nicotine-dependent patients
12/29/2004	EP1196616B1 Replication-competent anti-cancer vectors
12/29/2004	EP1196180B1 Treatment of angiogenesis dependent conditions with dextrin sulphate

1 ... 4842 4843 4844 4845 4846 4847 4848 4849 4850 4851 4852 4853 4854 4855 4856 4857 4858 4859 4860 4861 4862 ... 7860